[go: up one dir, main page]

WO2025097067A3 - Préparations cellulaires modifiées pour le traitement de l'hypophosphatasie - Google Patents

Préparations cellulaires modifiées pour le traitement de l'hypophosphatasie Download PDF

Info

Publication number
WO2025097067A3
WO2025097067A3 PCT/US2024/054285 US2024054285W WO2025097067A3 WO 2025097067 A3 WO2025097067 A3 WO 2025097067A3 US 2024054285 W US2024054285 W US 2024054285W WO 2025097067 A3 WO2025097067 A3 WO 2025097067A3
Authority
WO
WIPO (PCT)
Prior art keywords
hypophosphatasia
treatment
engineered cell
cell preparations
alp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/054285
Other languages
English (en)
Other versions
WO2025097067A9 (fr
WO2025097067A2 (fr
Inventor
Hanlan Liu
Sarah Grace LEACH
JR. Wayne BAINTER
Madison Ashley CLEMENTS
Richard A. Morgan
Timothy James MULLEN
Anja Fides Hohmann
Shamael Rabia Dastagir
Sharvari GUJJA
Sean Patrick KEEGAN
Andre STANLIE
Toshiro Kendrick Ohsumi
Monika MUSIAL-SIWEK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Be Biopharma Inc
Original Assignee
Be Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Be Biopharma Inc filed Critical Be Biopharma Inc
Publication of WO2025097067A2 publication Critical patent/WO2025097067A2/fr
Publication of WO2025097067A3 publication Critical patent/WO2025097067A3/fr
Publication of WO2025097067A9 publication Critical patent/WO2025097067A9/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/231—Interleukin-10 (IL-10)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/52—CD40, CD40-ligand (CD154)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne des procédés et des compositions pour la culture, la modification et l'administration de populations de cellules de lignée B modifiées qui produisent une ALP ou une protéine de fusion de celle-ci, telle qu'une protéine de fusion ALP-Fc comprenant une phosphatase alcaline et une région cristallisable de fragment d'immunoglobuline humaine.
PCT/US2024/054285 2023-11-02 2024-11-01 Préparations cellulaires modifiées pour le traitement de l'hypophosphatasie Pending WO2025097067A2 (fr)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US202363595741P 2023-11-02 2023-11-02
US63/595,741 2023-11-02
US202463623768P 2024-01-22 2024-01-22
US63/623,768 2024-01-22
US202463643222P 2024-05-06 2024-05-06
US63/643,222 2024-05-06
US202463660968P 2024-06-17 2024-06-17
US63/660,968 2024-06-17
US202463698944P 2024-09-25 2024-09-25
US63/698,944 2024-09-25

Publications (3)

Publication Number Publication Date
WO2025097067A2 WO2025097067A2 (fr) 2025-05-08
WO2025097067A3 true WO2025097067A3 (fr) 2025-07-10
WO2025097067A9 WO2025097067A9 (fr) 2025-08-07

Family

ID=95583311

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/054285 Pending WO2025097067A2 (fr) 2023-11-02 2024-11-01 Préparations cellulaires modifiées pour le traitement de l'hypophosphatasie

Country Status (1)

Country Link
WO (1) WO2025097067A2 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018170150A2 (fr) * 2017-03-16 2018-09-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Immunothérapie à base de cellules pouvant être greffées pour l'administration sur une longue période de protéines thérapeutiques
US10449236B2 (en) * 2014-12-05 2019-10-22 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
WO2022051555A2 (fr) * 2020-09-03 2022-03-10 Rampart Bioscience, Inc. Constructions de phosphatase alcaline solubles et vecteurs d'expression comprenant un polynucléotide codant pour des constructions de phosphatase alcaline solubles
WO2024220446A2 (fr) * 2023-04-17 2024-10-24 Be Biopharma, Inc. Préparations cellulaires modifiées pour le traitement de l'hémophilie

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10449236B2 (en) * 2014-12-05 2019-10-22 Alexion Pharmaceuticals, Inc. Treating seizure with recombinant alkaline phosphatase
WO2018170150A2 (fr) * 2017-03-16 2018-09-20 Seattle Children's Hospital (dba Seattle Children's Research Institute) Immunothérapie à base de cellules pouvant être greffées pour l'administration sur une longue période de protéines thérapeutiques
WO2022051555A2 (fr) * 2020-09-03 2022-03-10 Rampart Bioscience, Inc. Constructions de phosphatase alcaline solubles et vecteurs d'expression comprenant un polynucléotide codant pour des constructions de phosphatase alcaline solubles
WO2024220446A2 (fr) * 2023-04-17 2024-10-24 Be Biopharma, Inc. Préparations cellulaires modifiées pour le traitement de l'hémophilie

Also Published As

Publication number Publication date
WO2025097067A9 (fr) 2025-08-07
WO2025097067A2 (fr) 2025-05-08

Similar Documents

Publication Publication Date Title
PH12021550793A1 (en) Anti-SARS-CoV-2-Spike Glycoprotein Antibodies and Antigen-Binding Fragments
WO2020198695A8 (fr) Compositions, dispositifs et méthodes pour thérapie associée au facteur vii
AU2019204119B2 (en) Novel polypeptide and method of producing IMP using the same
EP0675904A4 (fr) Anticorps monoclonaux neutralisateurs humains contre le virus de l'immunodeficience humaine.
PH12021550001A1 (en) Novel fusion protein specific for cd137 and pd-l1
DE69535319D1 (de) Rekombinante il-5 antagonisten für die behandlung von il-5 bedingten krankheiten
WO2021207433A3 (fr) Épitopes d'anticorps neutralisant le sars-cov-2
PH12020551642A1 (en) Aav compositions, methods of making and methods of use
WO2019032936A8 (fr) Antibiotiques linconsamides et leurs utilisations
MX2023009360A (es) Anticuerpos anti- variable delta 1 de tcr.
WO2021072129A3 (fr) Protéines contenant de multiples acides aminés non naturels différents et procédés de fabrication et d'utilisation de telles protéines
WO2020172482A3 (fr) Protéines de fusion fc du domaine extracellulaire cd80 pour le traitement de tumeurs négatives pour pd-l1
PH12021552662A1 (en) FUSION POLYPEPTIDE COMPRISING Fc REGION OF IMMUNOGLOBULIN AND GDF15
WO2025097067A3 (fr) Préparations cellulaires modifiées pour le traitement de l'hypophosphatasie
WO2021226439A3 (fr) Relaxines modifiées et leurs méthodes d'utilisation
MX2021011754A (es) Composiciones, dispositivos y metodos para el tratamiento de la enfermedad de fabry.
WO2024030856A3 (fr) Protéines immunomodulatrices et méthodes associées
WO2020225799A3 (fr) Procédé de détermination de la concentration de protéine tau (t) et/ou protéine tau (t) phosphorylée
WO2021021603A3 (fr) Immunogènes e2 de vhc modifiés et compositions de vaccin associées
WO2022150654A3 (fr) Polypeptides de liaison à l'antigène spécifiques aux coronavirus et leurs utilisations
WO2024220446A3 (fr) Préparations cellulaires modifiées pour le traitement de l'hémophilie
WO2024186859A3 (fr) Compositions d'anticorps anti-tl1a et méthodes de traitement de la sarcoïdose
WO2024168241A3 (fr) Protéines de fusion fgf23 stabilisées, compositions et thérapie ciblée pour l'hyperphosphatémie
WO2023225667A3 (fr) Bactéries recombinantes pour la production d'acide indole-3-acétique (aia) et leurs utilisations
WO2023159136A3 (fr) Modification d'épitope de récepteurs de surface cellulaire